Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 4/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069015 | 0.91 | HCRTR1 (0.46) | GRM5HCRTR1HCRTR2 | |
| SCHEMBL16945623 | 0.84 | CHRM2 (0.43) | CHRM2HSD11B1GRM5HCRTR1HCRTR2 | |
| SCHEMBL17464832 | 0.80 | PTPN1 (0.52) | CHRM2GRM5HCRTR1HCRTR2 | |
| SCHEMBL15934090 | 0.80 | PTPN1 (0.52) | CHRM2GRM5HCRTR1HCRTR2 | |
| SCHEMBL16945704 | 0.80 | SPHK2 (0.51) | CHRM2 | |
| SCHEMBL20225486 | 0.79 | CHRM2 (0.41) | CHRM2HSD11B1GRM5 | |
| SCHEMBL16945621 | 0.76 | HCRTR1 (0.41) | CHRM2GRM5HCRTR1HCRTR2 | |
| SCHEMBL22628912 | 0.75 | HSD11B1 (0.54) | CHRM2HSD11B1EPHX2 | |
| SCHEMBL17464839 | 0.75 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL15934136 | 0.75 | CHRM2 (0.49) | CHRM2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403813-B2 | Azetidine amide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CHRM2 170/4885HSD11B1 1131/4885GRM5 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.